HC Wainwright Reaffirms Buy Rating for Affimed (NASDAQ:AFMD)

Affimed (NASDAQ:AFMD)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 318.41% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Stifel Nicolaus cut their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, November 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Affimed Trading Up 2.6 %

Affimed stock opened at $2.39 on Tuesday. The stock has a 50-day moving average price of $3.17 and a 200 day moving average price of $4.23. Affimed has a 52 week low of $2.25 and a 52 week high of $8.95. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13.

Hedge Funds Weigh In On Affimed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in shares of Affimed during the 3rd quarter valued at $44,000. Point72 Asset Management L.P. boosted its holdings in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the last quarter. FMR LLC grew its position in Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 4,086 shares during the period. Intellectus Partners LLC increased its stake in Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 10,250 shares during the last quarter. Finally, Choreo LLC acquired a new stake in Affimed during the second quarter worth about $54,000. Institutional investors and hedge funds own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.